دورية أكاديمية
أعرض في EDS

Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk.

التفاصيل البيبلوغرافية
العنوان: Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk.
المؤلفون: Callander NS; University of Wisconsin Carbone Cancer Center, Madison, WI, USA. nsc@medicine.wisc.edu., Silbermann R; Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA., Kaufman JL; Winship Cancer Institute, Emory University, Atlanta, GA, USA., Godby KN; University of Alabama at Birmingham Hospital, Birmingham, AL, USA., Laubach J; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Schmidt TM; University of Wisconsin Carbone Cancer Center, Madison, WI, USA., Sborov DW; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA., Medvedova E; Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA., Reeves B; Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Dhakal B; Division of Hematology/Oncology, Department of Medicine, Mayo Clinic Arizona, Phoenix, AZ, USA., Rodriguez C; Icahn School of Medicine at Mount Sinai, New York, NY, USA., Chhabra S; Division of Hematology/Oncology, Department of Medicine, Mayo Clinic Arizona, Phoenix, AZ, USA., Chari A; Icahn School of Medicine at Mount Sinai, New York, NY, USA., Bal S; University of Alabama at Birmingham Hospital, Birmingham, AL, USA., Anderson LD Jr; Myeloma, Waldenstrӧm's and Amyloidosis Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, USA., Dholaria BR; Vanderbilt University Medical Center, Nashville, TN, USA., Nathwani N; Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, Duarte, CA, USA., Hari P; Division of Hematology/Oncology, Department of Medicine, Mayo Clinic Arizona, Phoenix, AZ, USA., Shah N; Department of Medicine, University of California San Francisco, San Francisco, CA, USA., Bumma N; Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA., Holstein SA; Division of Oncology & Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA., Costello C; Moores Cancer Center, University of California San Diego, La Jolla, CA, USA., Jakubowiak A; University of Chicago Medical Center, Chicago, IL, USA., Wildes TM; Division of Oncology & Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA., Orlowski RZ; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Shain KH; Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL, USA., Cowan AJ; Division of Medical Oncology, University of Washington, Seattle, WA, USA., Pei H; Janssen Research & Development, LLC, Titusville, NJ, USA., Cortoos A; Janssen Scientific Affairs, LLC, Horsham, PA, USA., Patel S; Janssen Scientific Affairs, LLC, Horsham, PA, USA., Lin TS; Janssen Scientific Affairs, LLC, Horsham, PA, USA., Giri S; Division of Hematology & Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA., Costa LJ; University of Alabama at Birmingham Hospital, Birmingham, AL, USA., Usmani SZ; Memorial Sloan Kettering Cancer Center, New York, NY, USA. usmanis@mskcc.org., Richardson PG; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Voorhees PM; Levine Cancer Institute, Atrium Health Wake Forest Baptist, Charlotte, NC, USA. Peter.Voorhees@atriumhealth.org.
المصدر: Blood cancer journal [Blood Cancer J] 2024 Apr 22; Vol. 14 (1), pp. 69. Date of Electronic Publication: 2024 Apr 22.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't; Randomized Controlled Trial
اللغة: English
بيانات الدورية: Publisher: Nature Pub. Group Country of Publication: United States NLM ID: 101568469 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-5385 (Electronic) Linking ISSN: 20445385 NLM ISO Abbreviation: Blood Cancer J Subsets: MEDLINE
أسماء مطبوعة: Original Publication: New York, NY : Nature Pub. Group
مواضيع طبية MeSH: Multiple Myeloma*/drug therapy , Multiple Myeloma*/genetics , Multiple Myeloma*/therapy , Multiple Myeloma*/mortality , Antibodies, Monoclonal*/therapeutic use , Antibodies, Monoclonal*/administration & dosage , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects, Humans ; Female ; Male ; Middle Aged ; Aged ; Chromosome Aberrations ; Adult ; Lenalidomide/therapeutic use ; Lenalidomide/administration & dosage ; Lenalidomide/adverse effects ; Dexamethasone/administration & dosage ; Dexamethasone/therapeutic use
مستخلص: In the MASTER study (NCT03224507), daratumumab+carfilzomib/lenalidomide/dexamethasone (D-KRd) demonstrated promising efficacy in transplant-eligible newly diagnosed multiple myeloma (NDMM). In GRIFFIN (NCT02874742), daratumumab+lenalidomide/bortezomib/dexamethasone (D-RVd) improved outcomes for transplant-eligible NDMM. Here, we present a post hoc analysis of patients with high-risk cytogenetic abnormalities (HRCAs; del[17p], t[4;14], t[14;16], t[14;20], or gain/amp[1q21]). Among 123 D-KRd patients, 43.1%, 37.4%, and 19.5% had 0, 1, or ≥2 HRCAs. Among 120 D-RVd patients, 55.8%, 28.3%, and 10.8% had 0, 1, or ≥2 HRCAs. Rates of complete response or better (best on study) for 0, 1, or ≥2 HRCAs were 90.6%, 89.1%, and 70.8% for D-KRd, and 90.9%, 78.8%, and 61.5% for D-RVd. At median follow-up (MASTER, 31.1 months; GRIFFIN, 49.6 months for randomized patients/59.5 months for safety run-in patients), MRD-negativity rates as assessed by next-generation sequencing (10 -5 ) were 80.0%, 86.4%, and 83.3% for 0, 1, or ≥2 HRCAs for D-KRd, and 76.1%, 55.9%, and 61.5% for D-RVd. PFS was similar between studies and superior for 0 or 1 versus ≥2 HRCAs: 36-month PFS rates for D-KRd were 89.9%, 86.2%, and 52.4%, and 96.7%, 90.5%, and 53.5% for D-RVd. These data support the use of daratumumab-containing regimens for transplant-eligible NDMM with HCRAs; however, additional strategies are needed for ultra-high-risk disease (≥2 HRCAs). Video Abstract.
(© 2024. The Author(s).)
References: Hemasphere. 2021 Feb 03;5(2):e528. (PMID: 33554050)
N Engl J Med. 2018 Feb 8;378(6):518-528. (PMID: 29231133)
Haematologica. 2021 Jul 01;106(7):2004-2008. (PMID: 33440920)
Leukemia. 2019 Jan;33(1):159-170. (PMID: 29967379)
Lancet Oncol. 2014 Nov;15(12):e538-48. (PMID: 25439696)
Leukemia. 2014 Feb;28(2):269-77. (PMID: 23974982)
Oncologist. 2022 Jul 5;27(7):e589-e596. (PMID: 35462406)
JAMA Oncol. 2020 Nov 01;6(11):1759-1765. (PMID: 32970151)
Leukemia. 2018 Jan;32(1):102-110. (PMID: 28584253)
Blood. 2016 Jun 16;127(24):2955-62. (PMID: 27002115)
Lancet Oncol. 2016 Aug;17(8):e328-e346. (PMID: 27511158)
J Clin Oncol. 2022 Sep 1;40(25):2901-2912. (PMID: 34898239)
J Immunol. 2016 Aug 1;197(3):807-13. (PMID: 27316683)
J Immunol. 2011 Feb 1;186(3):1840-8. (PMID: 21187443)
Leukemia. 2021 Feb;35(2):573-584. (PMID: 32457357)
Hematology Am Soc Hematol Educ Program. 2021 Dec 10;2021(1):30-36. (PMID: 34889431)
MAbs. 2015;7(2):311-21. (PMID: 25760767)
Lancet Haematol. 2023 Nov;10(11):e890-e901. (PMID: 37776872)
Blood Adv. 2021 Feb 23;5(4):1092-1096. (PMID: 33606004)
Lancet Haematol. 2023 Oct;10(10):e825-e837. (PMID: 37708911)
Blood. 2020 Aug 20;136(8):936-945. (PMID: 32325490)
Lancet Oncol. 2021 Nov;22(11):1582-1596. (PMID: 34655533)
Lancet. 2019 Jul 6;394(10192):29-38. (PMID: 31171419)
Haematologica. 2012 Aug;97(8):1272-7. (PMID: 22371180)
Lancet. 2010 Dec 11;376(9757):1989-99. (PMID: 21131037)
Cytometry A. 2019 Mar;95(3):279-289. (PMID: 30536810)
J Natl Compr Canc Netw. 2020 Dec 02;18(12):1730-1737. (PMID: 33285523)
Blood. 2016 Jul 21;128(3):384-94. (PMID: 27222480)
معلومات مُعتمدة: P30 CA008748 United States CA NCI NIH HHS
المشرفين على المادة: 4Z63YK6E0E (daratumumab)
0 (Antibodies, Monoclonal)
F0P408N6V4 (Lenalidomide)
7S5I7G3JQL (Dexamethasone)
تواريخ الأحداث: Date Created: 20240422 Date Completed: 20240429 Latest Revision: 20240524
رمز التحديث: 20240524
مُعرف محوري في PubMed: PMC11035596
DOI: 10.1038/s41408-024-01030-w
PMID: 38649340
قاعدة البيانات: MEDLINE
الوصف
تدمد:2044-5385
DOI:10.1038/s41408-024-01030-w